Physician profile
J Dean Cole
NPI 1285629568
$4,208,197.70
in general payments reported to CMS, 2019-2025
10 companies · $196K in 2025
The $196K reported for 2025 was more than what 98% of Orthopaedic Trauma providers received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401K · 2020: $688K · 2021: $671K · 2022: $771K · 2023: $730K · 2024: $751K · 2025: $196K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.7M · Travel and Lodging: $506 · Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,676,582.70 |
| Travel and Lodging | $505.70 |
| Food and Beverage | $300.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Products, INC. | $2,254,473.94 | 2019-2025 | |
| Stryker Corporation | $1,915,941.88 | 2019-2024 | T2, Triathlon |
| Zimmer Biomet Holdings, INC. | $30,012.88 | 2019-2023 | Versanail |
| Reel Surgical, INC. | $3,600.00 | 2021-2022 | |
| Orthofix Medical, INC. | $3,301.33 | 2019-2022 | |
| Smith+Nephew, INC. | $698.09 | 2019-2023 | Real Intelligence |
| Pacira Pharmaceuticals Incorporated | $122.82 | 2023 | Iovera |
| Arthrex, INC. | $30.00 | 2020 | |
| Depuy Synthes Sales INC. | $16.76 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Dean Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.